MassBio Forum—Doing Business With China: Changing Regulatory Reforms and BD Opportunities in China

MassBio Forum—Doing Business With China: Changing Regulatory Reforms and BD Opportunities in China

Speaking Engagement

China is a torrid topic in today’s environment for emerging growth life science companies. With large markets and health care opportunities abounding both in China and in the United States, and with opportunities for MA-based life sciences companies to extend their own trajectories, understanding the landscape, horizons and nuances of the Chinese marketplace as well as predilections of Chinese investors and strategic partners, is critically important. This forum will present an overview of the rapidly changing regulatory and market landscape in China. Key topics include:

  • Overview of the landscape today and future outlook
  • Emergence of innovative Chinese pharmaceutical companies
  • Leveraging China to accelerate clinical development path
  • Protection of IP in China: Legal concerns and practical solutions
  • Impact of regulations on currency, taxes, material import/export, etc.
  • Departures from the norm: Joint ventures, strategic partnerships and global licensing

WilmerHale Partner Kenneth Zhou will be a speaker on this panel along with Kate Haviland, CBO of Blueprint Medicines, and Wei Zhao, VP of 6 Dimensions (formerly Wuxi Ventures). Helen Ho, Vice President and Head of Corporate Development at Blueprint Medicines will moderate.

Read More About the Event



Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.